PMID- 26496741
OWN - NLM
STAT- MEDLINE
DCOM- 20160808
LR  - 20181202
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 32
IP  - 12
DP  - 2015 Dec
TI  - Continuing EGFR-TKI treatment in combination with super-selective arterial 
      infusion chemotherapy beyond disease progression for patients with advanced 
      EGFR-mutant non-small cell lung cancer.
PG  - 256
LID - 10.1007/s12032-015-0704-x [doi]
AB  - Regional therapy has shown promising results in patients with an oligo-metastasis 
      after the occurrence of resistance to epidermal growth factor receptor tyrosine 
      kinase inhibitors (EGFR-TKIs). This study evaluated the efficacy and safety of 
      continuing EGFR-TKI therapy concurrently with arterial infusion chemotherapy in 6 
      patients (median age 55.9 years) with advanced EGFR-mutant non-small cell lung 
      cancer (NSCLC) who had a locally progressive, centrally located lung lesion after 
      EGFR-TKI therapy. The patients received a super-selective arterial infusion of 
      docetaxel (75 mg/m(2)) every 28 days concurrently with EGFR-TKI therapy until 
      further progressive disease (PD) or unacceptable adverse effects (AEs) occurred. 
      Treatment outcomes were assessed via progression-free survival (PFS) times 
      (PFS-1: time to PD after EGFR-TKI therapy; PFS-2: time to further PD after 
      arterial infusion chemotherapy with EGFR-TKI therapy), the occurrence of 
      treatment-related AEs, and patient responses to the QLQ-LC13 quality-of-life 
      questionnaire. Three of the 6 patients achieved partial responses, and three had 
      stable disease. The median PFS-1 was 10.42 months, and the median PFS-2 was 4.1 
      months (range, 2.1-5.7 months). The median overall survival (OS) was 28.6 months 
      (range, 24.1-32.9 months). All AEs were either grade 1 or grade 2 in severity, 
      and no unexpected AEs were observed. One patient died of lung cancer. The 
      patients reported significant reductions from baseline in symptoms of cough, 
      chest pain, dyspnea, and hemoptysis (P < 0.05 for all comparisons). Thus, 
      continuing EGFR-TKI therapy in combination with super-selective arterial infusion 
      chemotherapy beyond PD for patients with advanced EGFR-mutant NSCLC is feasible, 
      and this approach warrants further investigation.
FAU - Qi, Huiwei
AU  - Qi H
AD  - Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, School of 
      Medicine, 507, Zhengmin Road, Shanghai, 200433, China. Huiwei_queen@163.com.
FAU - Jiang, Sen
AU  - Jiang S
AD  - Department of Radiology, Shanghai Pulmonary Hospital, Tongji University, School 
      of Medicine, Shanghai, China. Jasfly77@vip.163.com.
FAU - Yu, Dong
AU  - Yu D
AD  - Department of Radiology, Shanghai Pulmonary Hospital, Tongji University, School 
      of Medicine, Shanghai, China. Yudong_mail@126.com.
FAU - Ni, Huijuan
AU  - Ni H
AD  - Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, School of 
      Medicine, 507, Zhengmin Road, Shanghai, 200433, China. Bj20021120@163.com.
FAU - Hu, Qiong
AU  - Hu Q
AD  - Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, School of 
      Medicine, 507, Zhengmin Road, Shanghai, 200433, China. 13601919755@163.com.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, School of 
      Medicine, 507, Zhengmin Road, Shanghai, 200433, China. zhangjie2172@163.com.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20151023
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Docetaxel
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - Infusions, Intra-Arterial/adverse effects
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Taxoids/administration & dosage/adverse effects/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Arterial infusion chemotherapy
OT  - Docetaxel
OT  - Non-small cell lung cancer
OT  - Progressive disease
OT  - Tyrosine kinase inhibitors
EDAT- 2015/10/27 06:00
MHDA- 2016/08/09 06:00
CRDT- 2015/10/27 06:00
PHST- 2015/10/12 00:00 [received]
PHST- 2015/10/15 00:00 [accepted]
PHST- 2015/10/27 06:00 [entrez]
PHST- 2015/10/27 06:00 [pubmed]
PHST- 2016/08/09 06:00 [medline]
AID - 10.1007/s12032-015-0704-x [pii]
AID - 10.1007/s12032-015-0704-x [doi]
PST - ppublish
SO  - Med Oncol. 2015 Dec;32(12):256. doi: 10.1007/s12032-015-0704-x. Epub 2015 Oct 23.